Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.

J Parkinsons Dis · 2015 · PMC4923744 · PMID 26406127

Europe PMC DOI

hedged sentence

0.0546

closest p · 1.1× alpha

0.0546

boldest claim

The sentences

nearly significantp = 0.0546so close (0.05 < p ≤ 0.1)

For patients with baseline dyskinesia, improvements over placebo were also significant ( p = 0.0153) in patients with or without changes in levodopa dose, and nearly significant ( p = 0.0546) in patients with no change in levodopa dose, suggesting that these improvements were not due to levodopa dose reductions.

also in 3,349 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.